TuHURA Biosciences (NASDAQ:HURA) Shares Down 1.3% – Time to Sell?

TuHURA Biosciences, Inc. (NASDAQ:HURA) shares traded down 1.3% on Tuesday . The stock traded as low as $2.21 and last traded at $2.21. 154,149 shares were traded during mid-day trading, a decline of 76% from the average daily volume of 637,012 shares. The stock had previously closed at $2.24.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on HURA shares. Citizens Jmp assumed coverage on shares of TuHURA Biosciences in a report on Monday, April 27th. They issued a “market outperform” rating and a $9.00 price target for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Friday. Citigroup initiated coverage on TuHURA Biosciences in a research note on Monday, April 27th. They set an “outperform” rating on the stock. Wall Street Zen lowered TuHURA Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, May 31st. Finally, Rodman & Renshaw started coverage on TuHURA Biosciences in a research note on Wednesday, April 15th. They issued a “buy” rating for the company. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, TuHURA Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

TuHURA Biosciences Stock Performance

The stock has a market capitalization of $140.73 million, a price-to-earnings ratio of -3.62 and a beta of -0.05. The firm’s fifty day simple moving average is $2.34 and its 200 day simple moving average is $1.82.

TuHURA Biosciences (NASDAQ:HURA) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). Analysts forecast that TuHURA Biosciences, Inc. will post -0.56 earnings per share for the current year.

Institutional Investors Weigh In On TuHURA Biosciences

Several institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its stake in TuHURA Biosciences by 111.4% in the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock worth $1,300,000 after purchasing an additional 307,260 shares during the period. Cetera Investment Advisers acquired a new stake in shares of TuHURA Biosciences in the 1st quarter valued at about $251,000. WealthShield Partners LLC acquired a new stake in shares of TuHURA Biosciences in the 1st quarter valued at about $164,000. Deutsche Bank AG lifted its holdings in shares of TuHURA Biosciences by 209.8% in the fourth quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock valued at $61,000 after purchasing an additional 54,051 shares in the last quarter. Finally, New York State Common Retirement Fund bought a new stake in shares of TuHURA Biosciences in the second quarter valued at about $97,000. 0.62% of the stock is owned by institutional investors.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.